Ron Epelbaum

6.3k total citations
114 papers, 4.8k citations indexed

About

Ron Epelbaum is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ron Epelbaum has authored 114 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 50 papers in Pathology and Forensic Medicine and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ron Epelbaum's work include Lymphoma Diagnosis and Treatment (49 papers), Medical Imaging Techniques and Applications (24 papers) and Pancreatic and Hepatic Oncology Research (17 papers). Ron Epelbaum is often cited by papers focused on Lymphoma Diagnosis and Treatment (49 papers), Medical Imaging Techniques and Applications (24 papers) and Pancreatic and Hepatic Oncology Research (17 papers). Ron Epelbaum collaborates with scholars based in Israel, United States and Switzerland. Ron Epelbaum's co-authors include Nissim Haim, Gil Bar‐Sela, Moshe Schaffer, Ora Israel, Eldad J. Dann, Menachem Ben-Shahar, Rachel Bar‐Shalom, Zeev Blumenfeld, Irit Avivi and Jacob M. Rowe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Ron Epelbaum

113 papers receiving 4.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron Epelbaum Israel 40 1.9k 1.6k 1.0k 854 821 114 4.8k
Therese A. Dolecek United States 25 648 0.3× 538 0.3× 789 0.8× 1.0k 1.2× 645 0.8× 45 4.8k
Pax H.B. Willemse Netherlands 39 1.6k 0.8× 488 0.3× 459 0.5× 766 0.9× 616 0.8× 110 4.2k
Bridget A. Robinson New Zealand 37 2.0k 1.0× 615 0.4× 697 0.7× 1.3k 1.6× 711 0.9× 140 4.4k
D L Trump United States 33 2.0k 1.0× 671 0.4× 1.6k 1.6× 1.1k 1.3× 411 0.5× 76 4.8k
Edward T. Creagan United States 37 2.6k 1.3× 723 0.5× 956 0.9× 1.5k 1.7× 535 0.7× 154 5.4k
Ondřej Topolčan Czechia 31 1.6k 0.8× 496 0.3× 1.0k 1.0× 1.3k 1.5× 1.1k 1.3× 254 4.2k
Susanne Osanto Netherlands 37 1.4k 0.7× 535 0.3× 766 0.8× 1.9k 2.3× 757 0.9× 95 5.1k
P M Wilkinson United Kingdom 31 1.0k 0.5× 607 0.4× 799 0.8× 553 0.6× 165 0.2× 87 3.4k
Scott Wadler United States 43 4.5k 2.3× 975 0.6× 1.9k 1.9× 2.0k 2.4× 610 0.7× 192 8.1k
Érick Gamelin France 42 4.2k 2.2× 676 0.4× 1.0k 1.0× 1.7k 2.0× 476 0.6× 138 6.3k

Countries citing papers authored by Ron Epelbaum

Since Specialization
Citations

This map shows the geographic impact of Ron Epelbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Epelbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Epelbaum more than expected).

Fields of papers citing papers by Ron Epelbaum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Epelbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Epelbaum. The network helps show where Ron Epelbaum may publish in the future.

Co-authorship network of co-authors of Ron Epelbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Epelbaum. A scholar is included among the top collaborators of Ron Epelbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Epelbaum. Ron Epelbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Shroff, Rachna T., Andrew Hendifar, Robert R. McWilliams, et al.. (2018). Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precision Oncology. 2018(2). 1–15. 137 indexed citations
3.
Ben‐Haim, Simona, et al.. (2016). Metabolic assessment of Merkel cell carcinoma. Nuclear Medicine Communications. 37(8). 865–873. 12 indexed citations
4.
Kluger, Yoram, et al.. (2015). Predictors of Early Recurrence of Adenocarcinoma of the Head of the Pancreas after Curative Resection. JOP, journal of the pancreas. 16(6). 2 indexed citations
5.
Bar‐Sela, Gil, Miri Cohen, Eran Ben‐Arye, & Ron Epelbaum. (2015). The Medical Use of Wheatgrass: Review of the Gap Between Basic and Clinical Applications. Mini-Reviews in Medicinal Chemistry. 15(12). 1002–1010. 38 indexed citations
6.
7.
Anacak, Yavuz, Robert C. Miller, A.M. Mamusa, et al.. (2010). Primary Mucosa-Associated Lymphoid Tissue Lymphoma of the Salivary Glands: A Multicenter Rare Cancer Network Study. International Journal of Radiation Oncology*Biology*Physics. 82(1). 315–320. 40 indexed citations
8.
Fischer, Doron, Rachel Bar‐Shalom, Eldad J. Dann, et al.. (2008). FDG avidity and PET/CT patterns in primary gastric lymphoma. European Journal of Nuclear Medicine and Molecular Imaging. 35(8). 1424–1430. 58 indexed citations
9.
Bar‐Sela, Gil, et al.. (2007). Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy. Psycho-Oncology. 16(11). 980–984. 140 indexed citations
10.
Bar‐Shalom, Rachel, Nissim Haim, Eldad J. Dann, et al.. (2003). Camera-based FDG PET and67Ga SPECT in Evaluation of Lymphoma: Comparative Study. Radiology. 227(2). 353–360. 41 indexed citations
11.
Bergman, Richard N., et al.. (2002). Clinicopathologic reassessment of non‐mycosis fungoides primary cutaneous lymphomas during 17 years. International Journal of Dermatology. 41(11). 735–743. 8 indexed citations
12.
Piccart, M., P.F. Bruning, RE Coleman, et al.. (2000). AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282). Ghent University Academic Bibliography (Ghent University). 13 indexed citations
13.
Epelbaum, Ron, et al.. (1999). Phase II study of gemcitabine (GEM) combined with radiation therapy (RT) in localized, unresectable pancreatic cancer. European Journal of Cancer. 35. S148–S149. 26 indexed citations
14.
Dirix, Luc, Jim Cassidy, Ron Epelbaum, et al.. (1996). EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. European Journal of Cancer. 32(11). 2019–2022. 45 indexed citations
15.
Haim, Nissim, Menachem Ben-Shahar, & Ron Epelbaum. (1995). Prolonged daily administration of oral etoposide in lymphoma following prior therapy with Adriamicin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer Chemotherapy and Pharmacology. 36(4). 352–355. 10 indexed citations
16.
Even‐Sapir, Einat, Rachel Bar‐Shalom, Ora Israel, et al.. (1995). Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake.. Journal of Clinical Oncology. 13(4). 942–946. 41 indexed citations
17.
Haim, Nissim, Edward Rosenblatt, Mira Wollner, et al.. (1992). Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin. Cancer Chemotherapy and Pharmacology. 30(3). 243–244. 13 indexed citations
18.
Teicher, B A, et al.. (1991). Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.. PubMed. 51(3). 780–4. 35 indexed citations
19.
Kuten, Abraham, et al.. (1988). Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma. International Journal of Radiation Oncology*Biology*Physics. 14(2). 273–279. 30 indexed citations
20.
Cohen, Yoram, et al.. (1984). The value of serum copper levels in non-Hodgkin's lymphoma. Cancer. 53(2). 296–300. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Therese A. Dolecek Breakdown of academic impact, for papers by Pax H.B. Willemse Breakdown of academic impact, for papers by Bridget A. Robinson Breakdown of academic impact, for papers by D L Trump Breakdown of academic impact, for papers by Edward T. Creagan Breakdown of academic impact, for papers by Ondřej Topolčan Breakdown of academic impact, for papers by Susanne Osanto Breakdown of academic impact, for papers by P M Wilkinson Breakdown of academic impact, for papers by Scott Wadler Breakdown of academic impact, for papers by Érick Gamelin
Rankless by CCL
2026